Immunotherapy for cat asthma

Thomas E. Van Metre, David G. Marsh, N Franklin Adkinson, Anne Kagey-Sobotka, Arouna Khattignavong, Philip S. Norman, Gary L. Rosenberg

Research output: Contribution to journalArticle

Abstract

In 22 patients with cat asthma who were highly sensitive to cat, we compared, double-blind, the effects of immunotherapy with cat-hair and dander extract (11 patients) with effects of placebo (11 patients). Patients were matched by the dose of the cat extract expressed in Food and Drug Administration (FDA) units of Fel d I (previously called cat allergen 1) required for end point reaction in intradermal skin test end point titration (STEPT), for in vitro leukocyte histamine release (LHR), and for the dose of cat extract producing a 20% fall in FEV1 (cat-extract PD20) in bronchoprovocation test. Patients were matched also for bronchoprovocation dose of methacholine producing a 20% fall in FEV1 (methacholine PD20). Patients were randomly assigned to one of two treatment groups. During immunotherapy, doses were increased to maintenance dose of 4.56 FDA units of Fel d I, or, if this were less, to the highest tolerated dose. Systemic reactions to cat-extract immunotherapy were mild and infrequent. Before and during immunotherapy, we measured (in FDA units of Fel d I) cat-extract PD20, cat-extract intradermal STEPT cat-extract in vitro LHR, serum levels of cat IgG and cat IgE, and methacholine PD20, After they had received 1 year of immunotherapy, patients receiving cat extract, in comparison to patients receiving placebo, had decreased cat-extract PD20 (p <0.01), diminished responses to cat-extract intradermal STEPT (p <0.025), increased IgE antibodies toward cat extract (p <0.01), increased IgG antibodies toward cat extract, Fel d I, and cat albumin (p <0.001), but no significant change in cat-extract in vitro LHR or in methacholine PD20, We conclude that cat-extract immunotherapy was well tolerated, significantly decreased skin and bronchial responses to cat extract, and significantly increased IgE antibodies to cat extract and IgG antibodies to cat extract, Fel d I, and cat albumin.

Original languageEnglish (US)
Pages (from-to)1055-1068
Number of pages14
JournalThe Journal of Allergy and Clinical Immunology
Volume82
Issue number6
DOIs
StatePublished - 1988

Fingerprint

Immunotherapy
Cats
Asthma
Skin Test End-Point Titration
Intradermal Tests
Methacholine Chloride
Histamine Release
United States Food and Drug Administration
Immunoglobulin E
Leukocytes
Antibodies
Immunoglobulin G
Albumins
Dander
Placebo Effect

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Van Metre, T. E., Marsh, D. G., Adkinson, N. F., Kagey-Sobotka, A., Khattignavong, A., Norman, P. S., & Rosenberg, G. L. (1988). Immunotherapy for cat asthma. The Journal of Allergy and Clinical Immunology, 82(6), 1055-1068. https://doi.org/10.1016/0091-6749(88)90144-3

Immunotherapy for cat asthma. / Van Metre, Thomas E.; Marsh, David G.; Adkinson, N Franklin; Kagey-Sobotka, Anne; Khattignavong, Arouna; Norman, Philip S.; Rosenberg, Gary L.

In: The Journal of Allergy and Clinical Immunology, Vol. 82, No. 6, 1988, p. 1055-1068.

Research output: Contribution to journalArticle

Van Metre, TE, Marsh, DG, Adkinson, NF, Kagey-Sobotka, A, Khattignavong, A, Norman, PS & Rosenberg, GL 1988, 'Immunotherapy for cat asthma', The Journal of Allergy and Clinical Immunology, vol. 82, no. 6, pp. 1055-1068. https://doi.org/10.1016/0091-6749(88)90144-3
Van Metre, Thomas E. ; Marsh, David G. ; Adkinson, N Franklin ; Kagey-Sobotka, Anne ; Khattignavong, Arouna ; Norman, Philip S. ; Rosenberg, Gary L. / Immunotherapy for cat asthma. In: The Journal of Allergy and Clinical Immunology. 1988 ; Vol. 82, No. 6. pp. 1055-1068.
@article{5de44a08972f4fa09d77246f4cb0ac00,
title = "Immunotherapy for cat asthma",
abstract = "In 22 patients with cat asthma who were highly sensitive to cat, we compared, double-blind, the effects of immunotherapy with cat-hair and dander extract (11 patients) with effects of placebo (11 patients). Patients were matched by the dose of the cat extract expressed in Food and Drug Administration (FDA) units of Fel d I (previously called cat allergen 1) required for end point reaction in intradermal skin test end point titration (STEPT), for in vitro leukocyte histamine release (LHR), and for the dose of cat extract producing a 20{\%} fall in FEV1 (cat-extract PD20) in bronchoprovocation test. Patients were matched also for bronchoprovocation dose of methacholine producing a 20{\%} fall in FEV1 (methacholine PD20). Patients were randomly assigned to one of two treatment groups. During immunotherapy, doses were increased to maintenance dose of 4.56 FDA units of Fel d I, or, if this were less, to the highest tolerated dose. Systemic reactions to cat-extract immunotherapy were mild and infrequent. Before and during immunotherapy, we measured (in FDA units of Fel d I) cat-extract PD20, cat-extract intradermal STEPT cat-extract in vitro LHR, serum levels of cat IgG and cat IgE, and methacholine PD20, After they had received 1 year of immunotherapy, patients receiving cat extract, in comparison to patients receiving placebo, had decreased cat-extract PD20 (p <0.01), diminished responses to cat-extract intradermal STEPT (p <0.025), increased IgE antibodies toward cat extract (p <0.01), increased IgG antibodies toward cat extract, Fel d I, and cat albumin (p <0.001), but no significant change in cat-extract in vitro LHR or in methacholine PD20, We conclude that cat-extract immunotherapy was well tolerated, significantly decreased skin and bronchial responses to cat extract, and significantly increased IgE antibodies to cat extract and IgG antibodies to cat extract, Fel d I, and cat albumin.",
author = "{Van Metre}, {Thomas E.} and Marsh, {David G.} and Adkinson, {N Franklin} and Anne Kagey-Sobotka and Arouna Khattignavong and Norman, {Philip S.} and Rosenberg, {Gary L.}",
year = "1988",
doi = "10.1016/0091-6749(88)90144-3",
language = "English (US)",
volume = "82",
pages = "1055--1068",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Immunotherapy for cat asthma

AU - Van Metre, Thomas E.

AU - Marsh, David G.

AU - Adkinson, N Franklin

AU - Kagey-Sobotka, Anne

AU - Khattignavong, Arouna

AU - Norman, Philip S.

AU - Rosenberg, Gary L.

PY - 1988

Y1 - 1988

N2 - In 22 patients with cat asthma who were highly sensitive to cat, we compared, double-blind, the effects of immunotherapy with cat-hair and dander extract (11 patients) with effects of placebo (11 patients). Patients were matched by the dose of the cat extract expressed in Food and Drug Administration (FDA) units of Fel d I (previously called cat allergen 1) required for end point reaction in intradermal skin test end point titration (STEPT), for in vitro leukocyte histamine release (LHR), and for the dose of cat extract producing a 20% fall in FEV1 (cat-extract PD20) in bronchoprovocation test. Patients were matched also for bronchoprovocation dose of methacholine producing a 20% fall in FEV1 (methacholine PD20). Patients were randomly assigned to one of two treatment groups. During immunotherapy, doses were increased to maintenance dose of 4.56 FDA units of Fel d I, or, if this were less, to the highest tolerated dose. Systemic reactions to cat-extract immunotherapy were mild and infrequent. Before and during immunotherapy, we measured (in FDA units of Fel d I) cat-extract PD20, cat-extract intradermal STEPT cat-extract in vitro LHR, serum levels of cat IgG and cat IgE, and methacholine PD20, After they had received 1 year of immunotherapy, patients receiving cat extract, in comparison to patients receiving placebo, had decreased cat-extract PD20 (p <0.01), diminished responses to cat-extract intradermal STEPT (p <0.025), increased IgE antibodies toward cat extract (p <0.01), increased IgG antibodies toward cat extract, Fel d I, and cat albumin (p <0.001), but no significant change in cat-extract in vitro LHR or in methacholine PD20, We conclude that cat-extract immunotherapy was well tolerated, significantly decreased skin and bronchial responses to cat extract, and significantly increased IgE antibodies to cat extract and IgG antibodies to cat extract, Fel d I, and cat albumin.

AB - In 22 patients with cat asthma who were highly sensitive to cat, we compared, double-blind, the effects of immunotherapy with cat-hair and dander extract (11 patients) with effects of placebo (11 patients). Patients were matched by the dose of the cat extract expressed in Food and Drug Administration (FDA) units of Fel d I (previously called cat allergen 1) required for end point reaction in intradermal skin test end point titration (STEPT), for in vitro leukocyte histamine release (LHR), and for the dose of cat extract producing a 20% fall in FEV1 (cat-extract PD20) in bronchoprovocation test. Patients were matched also for bronchoprovocation dose of methacholine producing a 20% fall in FEV1 (methacholine PD20). Patients were randomly assigned to one of two treatment groups. During immunotherapy, doses were increased to maintenance dose of 4.56 FDA units of Fel d I, or, if this were less, to the highest tolerated dose. Systemic reactions to cat-extract immunotherapy were mild and infrequent. Before and during immunotherapy, we measured (in FDA units of Fel d I) cat-extract PD20, cat-extract intradermal STEPT cat-extract in vitro LHR, serum levels of cat IgG and cat IgE, and methacholine PD20, After they had received 1 year of immunotherapy, patients receiving cat extract, in comparison to patients receiving placebo, had decreased cat-extract PD20 (p <0.01), diminished responses to cat-extract intradermal STEPT (p <0.025), increased IgE antibodies toward cat extract (p <0.01), increased IgG antibodies toward cat extract, Fel d I, and cat albumin (p <0.001), but no significant change in cat-extract in vitro LHR or in methacholine PD20, We conclude that cat-extract immunotherapy was well tolerated, significantly decreased skin and bronchial responses to cat extract, and significantly increased IgE antibodies to cat extract and IgG antibodies to cat extract, Fel d I, and cat albumin.

UR - http://www.scopus.com/inward/record.url?scp=0024268327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024268327&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(88)90144-3

DO - 10.1016/0091-6749(88)90144-3

M3 - Article

C2 - 2462581

AN - SCOPUS:0024268327

VL - 82

SP - 1055

EP - 1068

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 6

ER -